Insilico, WuXi AppTec unveil one piece of hit-generating AI pipeline

Insilico and WuXi AppTec's Nature Biotechnology study provides initial proof-of-concept for the AI company's de novo small molecule generation platform, but the companies have not yet revealed their methods for taking on orphan targets with no known crystal structures or ligands, one of the goals of their R&D partnership.

The paper, published Monday, describes the outcome of a "timed challenge" assessing how quickly Insilico Medicine Inc. (Rockville, Md.) can design biologically active targeted inhibitors using its generative tensorial reinforcement learning (GENTRL) method. CEO Alex Zhavoronkov told BioCentury the GENTRL algorithm described in the study is one of about 800 modules in its automated chemical design pipeline...